Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and efficacy of novobiocin and rifampicin-resistant Aeromonas hydrophila as novel vaccines in channel catfish and Nile tilapia.

Vaccine - 19 Oct 2011

Pridgeon Julia W, Klesius Phillip H

Abstract excerpt

Three attenuated Aeromonas hydrophila vaccines were developed from the virulent 2009 West Alabama isolates through selection for resistance to both novobiocin and rifampicin. When channel catfish (Ictalurus punctatus) were IP injected with 4×105 colony-forming unit (CFU) of the mutants, no fish died. However, when the same age and size matched channel catfish were IP injected with similar amount of their virulent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aeromonas hydrophila
Share to Alabama
Share to Antibodies, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bacterial Vaccines

Share to Cichlids

Share to Gram-Negative Bacterial Infections

Share to Novobiocin

Share to Vaccines, Attenuated

Source

Identifiers

PMID: 21872628
DOI: 10.1016/j.vaccine.2011.08.082

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and efficacy of novobiocin and rifampicin-resistant Aeromonas hydrophila as novel vaccines in channel catfish and Nile tilapia.PMID 21872628Read ↗

Biochemical and molecular characterization of the novobiocin and rifampicin resistant Aeromonas hydrophila vaccine strain AL09-71N+R compared to its virulent parent strain AL09-71.Semantic proximity Read ↗

The in vitro efficacy of oxytetracycline against re‐isolated pathogenic Aeromonas hydrophila carrying the cytolytic enterotoxin gene through hybrid catfish, Clarias macrocephalus (Günther, 1864) × Clarias gariepinus (Burchell, 1822) in ThailandSemantic proximity Read ↗

Advances in vaccines developed for bacterial fish diseases, performance and limitsSemantic proximity Read ↗

Advances and Challenges in Aeromonas hydrophila Vaccine Development: Immunological Insights and Future PerspectivesSemantic proximity Read ↗

New attenuated vaccine against columnaris disease in fish: choosing the right parental strain is critical for vaccine efficacy.Semantic proximity Read ↗

Analysis of virulence and immunogenic factors in Aeromonas hydrophila: Towards the development of live vaccinesSemantic proximity Read ↗

Development of attenuated erythromycin‐resistant Streptococcus agalactiae vaccine for tilapia ( Oreochromis niloticus ) cultureSemantic proximity Read ↗

An orally delivered, live‐attenuated Edwardsiella ictaluri vaccine efficiently protects channel catfish fingerlings against multiple Edwardsiella ictaluri field isolatesSemantic proximity Read ↗

Potential of naturally attenuated Streptococcus agalactiae as a live vaccine in Nile tilapia (Oreochromis niloticus)Semantic proximity Read ↗

Chitosan-tripolyphosphate nanoparticles as a novel vehicle for DNA vaccine delivery: combatting Aeromonas hydrophila in zebrafishSemantic proximity Read ↗

Effectiveness of the Edwardsiella ictaluri whole-cell vaccine in controlling enteric septicemia of catfish disease in striped catfish (Pangasianodon hypophthalmus)Semantic proximity Read ↗

Molecular characterization and bivalent vaccine development of Aeromonas hydrophila and Aeromonas veronii in Nile tilapia (Oreochromis niloticus)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.